This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Cronos (CRON) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will focus on pipeline progress and updates when Cronos (CRON) reports third-quarter results.
Tilray, Inc. (TLRY) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Tilray, Inc. (TLRY) closed at $100.98 in the latest trading session, marking a +1.5% move from the prior day.
Is A Disappointment in Store for Tilray (TLRY) Q3 Earnings?
by Zacks Equity Research
Investors will focus on pipeline progress and updates when Tilray (TLRY) reports third-quarter results.
Tilray, Inc. (TLRY) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Tilray, Inc. (TLRY) closed at $90.41 in the latest trading session, marking a -0.3% move from the prior day.
The Zacks Analyst Blog Highlights: Tilray, Cronos, Canopy Growth, GW Pharmaceuticals and Constellation Brands
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Tilray, Cronos, Canopy Growth, GW Pharmaceuticals and Constellation Brands
Tilray, Inc. (TLRY) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Tilray, Inc. (TLRY) closed at $120.79, marking a -1.48% move from the previous day.
Marijuana ETF Enters Bear Territory: What Lies Ahead?
by Sweta Killa
Despite entering into bear territory, the cannabis ETF is up more than 24% over the past three months and the outlook remains bright.
Marijuana Stocks Plummet to Record Low: What's Next?
by Zacks Equity Research
Legalization has long been considered a boon for the marijuana industry.
The Zacks Analyst Blog Highlights: Tilray, Coca-Cola, Constellation Brands, Canopy Growth and ETFMG
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Tilray, Coca-Cola, Constellation Brands, Canopy Growth and ETFMG
Canada Legalizes Marijuana: Stocks & ETF in Focus
by Neena Mishra
Canada legalized recreational pot today but it's "sell the news" event for pot stocks that have seen astronomical gains recently.
Are Options Traders Betting on a Big Move in Tilray (TLRY) Stock?
by Zacks Equity Research
Investors need to pay close attention to Tilray (TLRY) stock based on the movements in the options market lately.
Tilary Buys Alef Biotechnology to Build Base in Latin America
by Zacks Equity Research
Tilary (TLRY) acquires import and distribution partner, Alef Biotechnology to strengthen its base in Latin America.
The Zacks Analyst Blog Highlights: Tilray, Raytheon, Boyd Gaming, Altria Group and Simply Good Foods
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Tilray, Raytheon, Boyd Gaming, Altria Group and Simply Good Foods
Tilray, Inc. (TLRY) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Tilray, Inc. (TLRY) closed at $146.91, marking a +1.2% move from the previous day.
Get Over Marijuana, Indulge in These 4 Sin Stocks Instead
by Tirthankar Chakraborty
Products and services of sin stocks are relatively inelastic and the very nature of their business ensures a steady stream of consumers, irrespective of market conditions.
Pot Stocks & ETF: Risks and Rewards
by Neena Mishra
Here is what investors need to know about risks and rewards of investing in the emerging marijuana industry.
Top Wall Street Stories of the Third Quarter
by Sweta Killa
We discuss some of the events that dominated the headlines in the third quarter and influenced the market.
Wall Street's Reefer Madness, Micron Earnings, & More Stock News
by Ryan McQueeney
Ryan McQueeney and Maddy Johnson discuss the performance of Netflix and other streaming services at the Emmys. The team also chat about the alleged criminal probe facing Elon Musk and Tesla. Later, they discuss marijuana stocks and recap Micron's latest earnings report.
Is Goldilocks Market Coming?
by Zacks Equity Research
Is Goldilocks Market Coming?
How Much Longer for the Goldilocks Market?
by Mark Vickery
Investors who've been around the block a few times tend to look for something around the corner that threatens to stick a pin in this ever-expanding balloon.
Zacks Investment Ideas feature highlights: Tilray, Tesla and Microsoft
by Zacks Equity Research
Zacks Investment Ideas feature highlights: Tilray, Tesla and Microsoft
Company News For Sep 20, 2018
by Zacks Equity Research
Companies In The News are: TLRY,FB,CPRT,ABBV
Cannabis Company Tilray's (TLRY) Shares Up 856% Since July
by Zacks Equity Research
Tilray (TLRY) inks an import deal with the U.S. Drug Enforcement Administration for a trial on neurological movement disorder.
Know How Beverage Stocks Will Gain From Shift to Marijuana
by Rajani Lohia
Cannabis-infused drinks have emerged as an attractive alternative to the problems of the players in the U.S. beverage space, given the health benefits it offers.
Zacks Investment Ideas feature highlights: Tilray
by Zacks Equity Research
Zacks Investment Ideas feature highlights: Tilray